| Name | Title | Contact Details |
|---|---|---|
Dan Esrick |
General Counsel | Profile |
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.
ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our emtelliPro NLP engine transforms difficult-to-use, narrative medical text into valuable and actionable insights. Enable innovation. Improve competitiveness. Drive performance.
Novel therapeutics for metabolic and endocrine disorders
A happier, healthier you is our goal. Kitsap Mental Health Services provides comprehensive, compassionate and people-centered care.